menu
    • menu
    [{"orgOrder":0,"company":"Baiya Phytopharm","sponsor":"3M Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"25 Baiya SARS-CoV-2 Vax 2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Baiya Phytopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baiya Phytopharm \/ 3M Company","highestDevelopmentStatusID":"6","companyTruncated":"Baiya Phytopharm \/ 3M Company"},{"orgOrder":0,"company":"Baiya Phytopharm","sponsor":"National Vaccine Institute, Thailand","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Baiya SARS-CoV-2 Vaccine 1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Baiya Phytopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baiya Phytopharm \/ National Vaccine Institute, Thailand","highestDevelopmentStatusID":"6","companyTruncated":"Baiya Phytopharm \/ National Vaccine Institute, Thailand"},{"orgOrder":0,"company":"Baiya Phytopharm","sponsor":"National Vaccine Institute, Thailand","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"THAILAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Baiya SARS-CoV-2 Vaccine 2","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Baiya Phytopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Baiya Phytopharm \/ National Vaccine Institute, Thailand","highestDevelopmentStatusID":"6","companyTruncated":"Baiya Phytopharm \/ National Vaccine Institute, Thailand"},{"orgOrder":0,"company":"Baiya Phytopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Baiya SARS-CoV-2 Vaccine 2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Baiya Phytopharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baiya Phytopharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Baiya Phytopharm \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Baiya Phytopharm

    Menu

    Baiya Phytopharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Baiya Phytopharm

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Baiya Phytopharm

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Baiya SARS-CoV-2 Vaccine 2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for ...

                            Details : Baiya SARS-CoV-2 Vaccine 2 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 24, 2023

                            Lead Product(s) : Baiya SARS-CoV-2 Vaccine 2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Baiya Phytopharm

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Baiya Phytopharm

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : 3M Company

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            3M Adjuvant Boosts Immune Response to Plant-Based COVID-19 Vaccine in Thailand Clinical Trials

                            Details : Baiya’s SARS-CoV-2 Vax 2 is second-generation plant-produced vaccine modelled on prototype SARS-CoV-2 RBD antigen adjuvanted with 3M-052-AF-alum. Data from first cohort of 12 participants demonstrated no significant changes in vital signs during first ...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 29, 2022

                            Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : 3M Company

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Baiya Phytopharm

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Baiya Phytopharm

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Baiya SARS-CoV-2 Vaccine 2

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : National Vaccine Institute, Thailand

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 ...

                            Details : Baiya SARS-CoV-2 Vaccine 2 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            January 19, 2022

                            Lead Product(s) : Baiya SARS-CoV-2 Vaccine 2

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : National Vaccine Institute, Thailand

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Baiya Phytopharm

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Baiya Phytopharm

                            Thailand arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Baiya SARS-CoV-2 Vaccine 1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : National Vaccine Institute, Thailand

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19

                            Details : Baiya SARS-CoV-2 Vaccine 1 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Coronavirus.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 07, 2021

                            Lead Product(s) : Baiya SARS-CoV-2 Vaccine 1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : National Vaccine Institute, Thailand

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth